Abstracts tagged "longitudinal studies"

Abstract Number: 1110 • 2012 ACR/ARHP Annual Meeting
Radiologic Progression in Hand Osteoarthritis (OA) Over 2.6 Years – Data From the Sekoia Trial
Emmanuel Maheu¹, Christian Cadet² and Francis Berenbaum¹, ¹Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ²Rheumatology, Paris, France
Background/Purpose: Hand OA is a frequent polyarticular disease. Few is known with respect to its radiological progression over time, which in addition is difficult to…
Abstract Number: 1032 • 2012 ACR/ARHP Annual Meeting
Medial Meniscal Root Tears and the Association with Meniscal Extrusion, Prevalent Cartilage Damage and Longitudinal Cartilage Loss: The MOST Study
Mohamed Jarraya¹, David T. Felson², Daichi Hayashi¹, Frank Roemer³, Yuqing Zhang⁴, Jingbo Niu⁵, Michel Crema⁶, Martin Englund⁷, John A. Lynch⁸, Michael C. Nevitt⁹, James Torner¹⁰, C.E. Lewis¹¹ and Ali Guermazi⁶, ¹Department of Radiology, Boston University, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Radiology, Klinikum Augsburg, Augsburg, Germany, ⁴Clinical Epidemiology Unit, Boston University, Boston, MA, ⁵Boston University, Boston, MA, ⁶Radiology, Boston University, Boston, MA, ⁷Department of Orthopedics, Lund University, Lund, Sweden, ⁸Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, ⁹Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ¹⁰Epidemiology, University of Iowa, Iowa City, IA, ¹¹University of Alabama at Birmingham, Birmingham City, AL
Background/Purpose: The meniscal root is a ligamentous structure that anchors the posterior horn of the meniscus to the tibial plateau. The association of isolated meniscal…
Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…
Abstract Number: 653 • 2012 ACR/ARHP Annual Meeting
Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of Lupus Flare
Mikhail Olferiev¹, Kyriakos A. Kirou¹, Elena Gkrouzman¹, Dorthe Lundsgaard², Klaus S. Frederiksen³, Jan Fleckner⁴ and Mary K. Crow⁵, ¹Hospital for Special Surgery, New York, NY, ²Inflammation Science, Biopharmaceuticals Research Unit, Novo Nordisk A/S, Måløv, Denmark, ³Novo Nordisk A/S, Søborg, Denmark, ⁴NovoNordisk, Copenhagen, Denmark, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Lupus, a chronic autoimmune disease, is characterized by a variable clinical course, with periods of active disease termed flares. The severity of flares can…
Abstract Number: 2514 • 2012 ACR/ARHP Annual Meeting
Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population
Aniket A. Kawatkar¹, Cecilia Portugal¹, Li-Hao Chu² and Rajan Iyer³, ¹Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, ³Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: As epidemiologic studies throughout the world have shown significant variations, we sought to characterize racial differences in longitudinal epidemiologic trends of adult rheumatoid arthritis…
Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca⁵, ¹Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Clinic Hospital "Sf. Maria", Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…
Abstract Number: 2469 • 2012 ACR/ARHP Annual Meeting
A Virtual Knee Joint Replacement Clinical Endpoint Based On Longitudinal Trends and Thresholds in Koos Knee Pain and Function in Osteoarthritis Initiative Participants
Robert M. Boudreau¹, David J. Hunter², Zhijie Wang³, Frank Roemer⁴, Felix Eckstein⁵, Michael J. Hannon³, Ali Guermazi⁶ and C. Kent Kwoh⁷, ¹Epidemiology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ³Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Radiology, Boston University School of Medicine, Boston, MA, ⁵Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ⁶Boston University, Boston, MA, ⁷School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Knee joint replacement (KR) is a cost-effective procedure with good long-term outcomes, but has limitations as an endpoint in OA intervention trials. A definition…
Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting
Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis
Bjorn Svensson¹, Maria LE Andersson², Sidona-Valentina Bala³, Kristina Forslind⁴ and Ingiäld Hafström⁵, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Department of Health Sciences,, Lund University, Lund, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 232 • 2012 ACR/ARHP Annual Meeting
The Natural History of Sporadic Inclusion Body Myositis – an Observational Longitudinal Study
Pedro Machado¹, Andrea Cortese¹, Jasper Morrow¹, Liz Dewar¹, Andy Hiscock¹, Adrian Miller¹, Stefen Brady², David Hilton-Jones², Matt Parton¹ and Michael G. Hanna¹, ¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ²Oxford Muscle and Nerve Centre, John Radcliffe Hospital, Oxford, United Kingdom
Background/Purpose: Our aim was to assess prospectively the clinical features and functional impact of inclusion body myositis (IBM), to identify reliable outcome measures for future…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].